Evaluation of the prognostic value of RANK, RANKL, OPG and OPN mRNA expression in high-risk early breast cancer patients treated with anthracycline-containing adjuvant chemotherapy.

Eleni Timotheadou,Flora Zagouri,Maria Skondra,Pavlos Papakostas,Elke Veltrup,Konstantine T Kalogeras,Vasilios Karavasilis,George Fountzilas,Zoi Alexopoulou,Helena Linardou,Helen Gogas,Angelos Koutras,Maria Sotiropoulou,Gerasimos Aravantinos,George Klouvas,Meletios A Dimopoulos,P Kosmidis ,George Pentheroudakis ,Ralph M Wirtz ,Alexandra Papoudou‐Bai

doi:10.1200/jco.2016.34.15_suppl.e23244

Evaluation of the prognostic value of RANK, RANKL, OPG and OPN mRNA expression in high-risk early breast cancer patients treated with anthracycline-containing adjuvant chemotherapy.

Eleni Timotheadou, Flora Zagouri + Show 18 more

https://doi.org/10.1200/jco.2016.34.15_suppl.e23244

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2016
Citations: 1

Affiliation: Hellenic Cooperative Oncology Group, Datamed Systems Integration (Greece), Hellenic Oncology Research Group

#High-risk Early Breast Cancer Patients #Anthracycline-containing Adjuvant Chemotherapy #Prevention Of Bone Metastases #OPN mRNA Expression #High-risk Breast Cancer Patients #OPG mRNA Expression #RANK mRNA Expression #RANKL mRNA Expression #Breast Cancer Patients #OPG mRNA

Abstract
Full-Text
Similar Papers

Abstract

Listen

e23244Background: Prevention of bone metastases is a major issue for breast cancer patients, as it would improve quality of life in a population where long survival with metastatic disease is antic...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Evaluation of the prognostic value of RANK, RANKL, OPG and OPN mRNA expression in high-risk early breast cancer patients treated with anthracycline-containing adjuvant chemotherapy.